What is OptionOne?
OptionOne operates as a specialty pharmacy, delivering home and alternate-site infusion therapies. The company distinguishes itself through a comprehensive clinical approach, offering high-touch monitoring and personalized service to guide patients through customized infusion therapy support. OptionOne administers IV treatments for acute and chronic illnesses, with a particular focus on conditions such as Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, and Immune Deficiencies. Their commitment to quality care is validated by national accreditation standards from the Accreditation Commission for Health Care (ACHC) for its Pharmacy, Ambulatory Infusion Center, Infusion Nursing Services, and Pharmacy Services.
How much funding has OptionOne raised?
OptionOne has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in OptionOne
PPP
Public-Private Partnership
What's next for OptionOne?
The recent major strategic investment indicates a phase of accelerated growth and market expansion for OptionOne. This capital infusion is likely to be directed towards enhancing service delivery capabilities, expanding geographic reach, and potentially investing in new therapeutic areas or advanced patient support technologies. The company's focus on chronic disease management and high-acuity infusion therapies positions it well to capitalize on the growing demand for specialized home healthcare solutions.
See full OptionOne company page
